RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer.
PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
Determine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast.
OUTLINE: This is a pilot study.
Patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Histologically confirmed primary adenocarcinoma of the breast
Stage I-III disease No evidence of metastatic disease Newly diagnosed disease
Hormone receptor status:
Estrogen receptor-positive- or -negative tumor
PATIENT CHARACTERISTICS:
Sex
Not specified
Menopausal status
Not specified
Performance status
Not specified
Life expectancy
Not specified
Hematopoietic
Not specified
Hepatic
Not specified
Renal
Not specified
Other
Not pregnant No Crohn's disease No arthritis No psoriasis No lupus erythematosus No multiple sclerosis No other severe active inflammation Not C-reactive protein positive No HIV positivity No other serious medical or psychiatric illness
